Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue
31.3.2026 15:00:00 CEST | Business Wire | Press Release
Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue.
As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions.
“What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartner. “By redefining partner marketing automation and embedding it directly into our revenue orchestration platform, we enable vendors to activate partners faster, automate campaigns at scale, and clearly see how those efforts translate into pipeline and growth.”
With this release, vendors can launch and automate multi-channel campaigns across email, social and paid media all within one system of record.
Impartner now supports lifecycle-triggered campaigns that activate automatically based on lead events, such as lead creation or movement into nurture. This event-driven automation replaces static, time-based drips with responsive lifecycle execution, which reduces manual effort while increasing speed to engagement.
Enhancements to the social media capabilities now enable user-level account connections and editable partner posts, allowing partner sales representatives to publish through their own profiles while vendors retain control over messaging and creative permissions. This approach balances brand governance with authentic, localized engagement.
A new visual, no-code email builder, built on Impartner’s proven News on Demand framework, enables seamless to- and through partners email communication, eliminates mandatory HTML uploads and simplifies campaign creation and allows for partner-level editability. The builder also supports AI translations and future AI enhancements.
In addition, Impartner differentiates in the market with its combination of “Partner Self Service” and “Do It For Me” execution options, being the only provider allowing partners to take control and edit campaign content or opt into fully automated vendor-managed campaigns consisting out of emails, social posts and paid ads, reducing friction for partners without dedicated marketing resources and accelerating co-selling execution.
Impartner also continues to differentiate itself with its unique Partner Marketing AdTech solution, an AI-powered paid ads automation solution available natively within the platform.
Industry analysts recognize Impartner as best-in-class in For-Partner Marketing and uniquely differentiated for its combination of AdTech and pipeline management capabilities, a combination that has delivered some of the most scalable and measurable customer success outcomes in the market.
Through its predictive AI integration, Impartner enables fully automated optimization across keywords, bids, audiences, and budgets using the big data and conversion data from all partner campaigns together across all geographics. Campaigns automatically adjust based on performance signals, increasing lead conversion and revenue data while significantly lowering cost per lead.
No other partner platform provides this level of embedded, AI-driven paid media automation. By integrating paid search directly into Partner Marketing Automation, Impartner transforms partner-funded advertising into a scalable, performance-driven growth engine without requiring advertising expertise at the partner level, on performance signals, increasing lead conversion while lowering cost per lead.
Learn more about Impartner’s partner marketing automaton (PMA) and request a demo here.
About Impartner
Impartner is the world’s leading partner revenue orchestration platform. Built on a foundation of partner relationship management (PRM), Impartner helps organizations run partner-led growth as a core part of their business, bringing together partner management, partner marketing, deal execution, hyperscaler GTM, automation, and analytics in one platform. Designed for how partner programs operate today, Impartner gives revenue and partner teams the ability to automate go-to-market execution, scale marketplace motions, and see exactly how partners contribute to pipeline and revenue. Learn more at impartner.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331532922/en/
Contacts
For media inquiries, please contact:
Lola Phonpadith
Communications Strategist
Lola.phonpadith@impartner.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom